Aiming for a bull's-eye: Targeting antifungals to fungi with dectin-decorated liposomes

Area of Science:

• Mycology and Infectious Diseases
• Drug Delivery Systems
• Nanotechnology in Medicine

Background:

• Invasive fungal diseases (IFDs) affect millions globally, with mortality rates exceeding 40%.
• Current antifungal therapies face challenges including insufficient efficacy, toxicity, emerging resistance, and limited new drug classes.
• Increased risk of IFDs in immunocompromised patients and those with medical devices necessitates improved treatment strategies.

Purpose of the Study:

• To introduce DectiSomes, a novel liposomal drug delivery system designed to enhance antifungal drug efficacy.
• To evaluate the targeted delivery and antifungal activity of DectiSomes against key fungal pathogens.
• To assess the potential of DectiSomes to overcome limitations of current antifungal therapies.

Main Methods:

• Development of DectiSomes by packaging antifungal drugs into liposomes functionalized with carbohydrate recognition domains.
• In vitro assessment of DectiSomes' binding and killing efficacy against Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus.
• In vivo evaluation of DectiSomes' efficacy in a mouse model of pulmonary aspergillosis.

Main Results:

• DectiSomes demonstrated orders of magnitude increases in binding to and killing of target fungi compared to untargeted liposomal drugs in vitro.
• Significant improvement in efficacy was observed in mouse models of pulmonary aspergillosis.
• The targeted delivery mechanism of DectiSomes effectively concentrates antifungals at the site of infection.

Conclusions:

• DectiSomes represent a promising advancement in antifungal drug delivery, significantly enhancing therapeutic efficacy.
• This novel approach has the potential to address the critical unmet needs in treating invasive fungal diseases.
• DectiSomes could establish a new paradigm for antifungal drug treatment, improving patient outcomes.